Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-A33: Pembrolizumab in Japanese rrPMBCL
NCT04317066Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2020
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Merck & Co. Primary endpoints: Objective Response Rate at 24 months, Number of Participants Who Experienced at Least One Adverse Event at 27 months and 1 more. Started Jun 2020; status: completed.
02
Drugs
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT04317066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04317066.